Arcadia Biosciences Financials - Benzinga

Arcadia Biosciences Inc

RKDANASDAQ

Trade with Public

Trade with Public

$0.3076

-0.0084-2.66%

近くで: Sep 25, 5:00 PM EST

$0.2893

-0.0183-5.95%

時間外: 6:31 PM EST

概要ニュース業績予想目標株価財務センチメント株主構成比較株式レポート

Arcadia Biosciences Financials

Arcadia Biosciences (RKDA) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Arcadia Biosciences Q2 EPS $(2.09) Up From $(3.26) YoY, Sales $1.443M Down From $1.455M YoY

Arcadia Biosciences (NASDAQ:RKDA) reported quarterly losses of $(2.09) per share. This is a 35.89 percent increase over losses of $(3.26) per share from the same period last year. The company reported $1.443 million in

Benzinga Newsdesk

PRO
Arcadia Biosciences Q1 EPS $(2.11) Misses $(0.80) Estimate, Sales $1.100M Miss $1.600M Estimate

Arcadia Biosciences (NASDAQ:RKDA) reported quarterly losses of $(2.11) per share which missed the analyst consensus estimate of $(0.80) by 163.75 percent. This is a 211.05 percent decrease over earnings of $1.90 per

Benzinga Newsdesk

PRO
Arcadia Biosciences Q4 EPS $(0.97) Misses $(0.66) Estimate, Sales $901.000K Miss $1.400M Estimate

Arcadia Biosciences (NASDAQ:RKDA) reported quarterly losses of $(0.97) per share which missed the analyst consensus estimate of $(0.66) by 46.97 percent. This is a 67.45 percent increase over losses of $(2.98) per share

Benzinga Newsdesk

PRO
Arcadia Biosciences Q3 EPS $0.63, Sales $1.302M Miss $1.900M Estimate

Benzinga Newsdesk

PRO
Arcadia Biosciences Q2 EPS $(3.26) Misses $(0.79) Estimate, Sales $1.455M Miss $1.600M Estimate

Arcadia Biosciences (NASDAQ:RKDA) reported quarterly losses of $(3.26) per share which missed the analyst consensus estimate of $(0.79) by 312.66 percent. This is a 517.95 percent decrease over earnings of $0.78 per

Benzinga Newsdesk

PRO
CORRECTION: Arcadia Biosciences Q1 EPS $1.90 Beats $(0.76) Estimate, Sales $1.20M Miss $1.60M Estimate

Arcadia Biosciences (NASDAQ:RKDA) reported quarterly earnings of $1.90 per share which beat the analyst consensus estimate of $(0.76) by 350 percent. This is a 206.74 percent increase over losses of $(1.78) per share

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved